Disposition of 2700 shares by Natarajan Sethuraman of Entrada Therapeutics at 20.0403 subject to Rule 16b-3

TRDA Stock  USD 20.17  0.15  0.74%   
About 75% of Entrada Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Entrada Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Entrada Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Entrada Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
Filed transaction by Entrada Therapeutics Officer: President, Research & Develop.. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Read at macroaxis.com
Disposition of 2700 common stock at 20.0403 of Entrada Therapeutics by Natarajan Sethuraman on 13th of November 2024. This event was filed by Entrada Therapeutics with SEC on 2024-11-13. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Entrada Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Entrada Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Entrada Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Entrada Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Entrada Therapeutics Fundamental Analysis

We analyze Entrada Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Entrada Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Entrada Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Working Capital

Working Capital Comparative Analysis

Entrada Therapeutics is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Entrada Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Entrada Therapeutics stock to make a market-neutral strategy. Peer analysis of Entrada Therapeutics could also be used in its relative valuation, which is a method of valuing Entrada Therapeutics by comparing valuation metrics with similar companies.

Peers

Entrada Therapeutics Related Equities

PEPGPepGen   6.37   
0%
61.0%
PHVSPharvaris   3.29   
0%
31.0%
MOLNMolecular Partners   2.04   
0%
19.0%
GNTAGenenta Science   1.92   
0%
18.0%
OPTOpthea   1.62   
0%
15.0%
EWTXEdgewise Therapeutics   1.33   
0%
12.0%
CNTACentessa Pharmaceuticals   1.00   
0%
9.0%
IRONDisc Medicine   0.75   
0%
7.0%
ELYMEliem Therapeutics   0.31   
2.0%
0%
CRNXCrinetics Pharmaceuticals   1.39   
13.0%
0%
LRMRLarimar Therapeutics   2.10   
20.0%
0%
CGEMCullinan Oncology   2.81   
27.0%
0%
VIGLVigil Neuroscience   2.92   
28.0%
0%
GLUEMonte Rosa   3.52   
33.0%
0%
TYRATyra Biosciences   3.78   
36.0%
0%
PMVPPmv Pharmaceuticals   4.73   
45.0%
0%
RLYBRallybio Corp   6.19   
59.0%
0%
THRDThird Harmonic   10.39   
100.0%
0%

Complementary Tools for Entrada Stock analysis

When running Entrada Therapeutics' price analysis, check to measure Entrada Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entrada Therapeutics is operating at the current time. Most of Entrada Therapeutics' value examination focuses on studying past and present price action to predict the probability of Entrada Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entrada Therapeutics' price. Additionally, you may evaluate how the addition of Entrada Therapeutics to your portfolios can decrease your overall portfolio volatility.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities